To search for these other autocrine factors that can activate JNK targets and counteract the anti-AML effects of NF-κB inhibitors, we first analyzed the expression profile of inflammatory cytokines in 580 primary human AML samples in our microarray data (Figure 3A). The gene discussed is MAPK8; the disease is acute myeloid leukemia.